COMPASS Pathways (NASDAQ:CMPS) Receives "Sell (D-)" Rating from Weiss Ratings

Key Points

• COMPASS Pathways (NASDAQ:CMPS) has received a "Sell (D-)" rating from Weiss Ratings, amidst a broader analysis showing mixed ratings from various analysts.
• Despite the negative rating from Weiss, other analysts like Canaccord Genuity have a "Buy" rating with a target price of $15.00, indicating some confidence in the stock's potential.
• COMPASS Pathways reported a loss of ($0.38) earnings per share in its last quarterly earnings, slightly missing consensus estimates, and analysts anticipate a yearly EPS of -2.33.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report)'s stock had its "sell (d-)" rating restated by Weiss Ratings in a report issued on Wednesday,Weiss Ratings reports.

CMPS has been the topic of several other reports. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $15.00 target price on shares of COMPASS Pathways in a research report on Friday, August 1st. Evercore ISI reaffirmed an "in-line" rating and issued a $6.00 target price (down from $11.00) on shares of COMPASS Pathways in a research report on Monday, June 23rd. Finally, HC Wainwright dropped their target price on COMPASS Pathways from $45.00 to $40.00 and set a "buy" rating on the stock in a research report on Monday, August 4th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, COMPASS Pathways currently has an average rating of "Moderate Buy" and an average target price of $16.29.

COMPASS Pathways Stock Performance

CMPS traded up $0.36 during trading hours on Wednesday, hitting $6.60. 2,665,147 shares of the stock were exchanged, compared to its average volume of 1,525,381. The stock has a 50-day simple moving average of $4.95 and a 200-day simple moving average of $4.15. COMPASS Pathways has a 12 month low of $2.25 and a 12 month high of $6.75. The stock has a market cap of $633.20 million, a price-to-earnings ratio of -3.59 and a beta of 2.21. The company has a debt-to-equity ratio of 0.16, a current ratio of 8.82 and a quick ratio of 8.82.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.01). Analysts anticipate that COMPASS Pathways will post -2.33 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Flagship Harbor Advisors LLC boosted its stake in COMPASS Pathways by 27.7% during the first quarter. Flagship Harbor Advisors LLC now owns 14,446 shares of the company's stock valued at $41,000 after buying an additional 3,134 shares in the last quarter. Conservest Capital Advisors Inc. boosted its stake in COMPASS Pathways by 32.5% during the second quarter. Conservest Capital Advisors Inc. now owns 20,363 shares of the company's stock valued at $57,000 after buying an additional 5,000 shares in the last quarter. GAMMA Investing LLC boosted its stake in COMPASS Pathways by 93.6% during the first quarter. GAMMA Investing LLC now owns 10,349 shares of the company's stock valued at $30,000 after buying an additional 5,003 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in COMPASS Pathways by 46.7% during the second quarter. China Universal Asset Management Co. Ltd. now owns 18,272 shares of the company's stock valued at $51,000 after buying an additional 5,817 shares in the last quarter. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd boosted its stake in COMPASS Pathways by 67.0% during the second quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 23,842 shares of the company's stock valued at $67,000 after buying an additional 9,569 shares in the last quarter. 46.19% of the stock is owned by institutional investors and hedge funds.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.